This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Px330-EGFP-LRRK2-CRISPR/Cas9
By Khaja Mohieddin Syed, PhD, Yogendra Verma, MSc, Oriol Busquets Figueras, PhD, Hanqin Li, PhD, Donald Rio, PhD, Frank Soldner, MD, Dirk Hockemeyer, PhD, Helen Bateup, PhD, Gabriella R Pangilinan, Nitzan Kutnowski and Luke Gilbert, PhD
Output Details
Description
It can be used to introduce LRRK2-G2019S mutation using CRISPR/Cas9 based genome editing.
Tags
- Genome editing
- LRRK2
Meet the Authors
-
-
-
-
-
-
-
-
-
Gabriella R Pangilinan
-
Nitzan Kutnowski
-
Related Research
Highly efficient generation of isogenic pluripotent stem cell models using prime editing
Prime editing (PE) simplifies creating human pluripotent stem cell (hPSC) disease models by optimizing mRNA delivery with editing efficiency increased up to 13-fold, enabling correction or introduction of Parkinson's disease mutations in hPSCs.
In vitro synthesis of PE2 (nCas9-MMLV RT fusion) polyA mRNA using T7 RNA polymerase
We describe the preparation of synthetic capped and polyadenylated messenger RNA (mRNA) encoding a Cas9 nickase-reverse transcriptase fusion protein (PE2) for use in genome editing with a method called prime editing.
pU6-pegRNA-SNCA-A30P
It can be used to introduce SNCA-A30P mutation using prime editing.